http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112014009050-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_282d8844066f5f683bc2463742373508 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_436a7558180580641933693d5428a139 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2012-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd242b29544217226aa44f9d3b50ecf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5911b279dfde58625fb2a2e6cb63cdbc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_927bdf232b9e7a86456026774ac43824 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e158cc9781a536cad9b36d72079cb8d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2d3f4ee585eae84fcc9b9067a69e5cf |
| publicationDate | 2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112014009050-B1 |
| titleOfInvention | Pyrrolbenzodiazepine antibody-drug conjugate, pharmaceutical composition comprising the same, as well as pyrrolebenzodiazepine compounds |
| abstract | pyrrolbenzodiazepines and conjugates thereof conjugate of formula (a): wherein the dashed lines indicate the optional presence of a double bond between cl and c2 or c2 and c3; r2 is independently selected from h, oh, =0, =ch2, cn, r, or, =ch-rd, =c(rd)2, o-so2-r, co2r and cor, and optionally still selected from from halo or dihalo; where rd is independently selected from r, co2r, cor, cho, co2h and halo; r6 and r9 are independently selected from h, r, oh, or, sh, sr, nh2, nhr, nrr', no2, me3sn and halo; r7 is independently selected from h, r, oh, or, sh, sr, nh2, nhr, nrr', noz, messn and halo; y is selected from a single bond and a group of the formulas a1 or a2: (a") (a2) where n shows where the group attaches to the n10 of the pbd moiety; rl1 and rl2 are independently selected from h and methyl or together with the carbon atom to which they are attached form a cyclopropylene group; cba represents a cell-binding agent; q is independently selected from o, s and nh; r11 is h or r or, when q is o , so3m, where m is a metal cation; r and r' are each independently selected from optionally substituted c1-12 alkyl, c3-20 heterocyclyl and c5-20 aryl groups and, optionally with respect to the nrr', r and r' group together with the nitrogen atom to which they are attached form an optionally substituted 4, 5, 6 or 7 membered heterocyclic ring; wherein r12 r16, r19 and r17 are as defined for r2, r6, r9 and r7 respectively; wherein r" is a c3-12 alkylene group, the chain of which may be interrupted by one or further heteroatoms, for example o, s, n(h), nme and/or aromatic rings, for example benzene or pyridine, wherein these rings are optionally substituted; x and x' are independently selected from o, s and n(h). |
| priorityDate | 2011-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.